Source (SRCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Trupanion (TRUP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade ...

Home Bancorp (HBCP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Top 10 Dividend Kings ranked for reliability, dividend safety, and value—featuring ABM and strict payout screens. Click for ...

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 14, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data ...

Q4 earnings Jan 27 with $2.10 EPS expected. Down 34% yearly but analysts maintain Strong Buy rating. Senate probe creates ...

Schneider National (NYSE:SNDR) is set to give its latest quarterly earnings report on Thursday, 2026-01-29. Here's what ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $92.6, a high estimate of $109.00, ...

Formerly MTBC, CareCloud ( CCLD) is a healthcare IT company developing AI-driven cloud-based solutions for revenue cycle management (RCM), electronic health records (EHR), and practice management ...

Rising market volatility has pushed dividend-paying stocks back into focus. Investors often turn to these names when markets get rough.

DCB Bank posts its best-ever quarterly profit, guides for sustained margin expansion and higher ROEs, and still trades below 1x FY27 book — re-rating story remains intact.

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.